IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Hill-Rom (HRC) Stock Down With Dull Patient Support Systems
by Zacks Equity Research
Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.
LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval
by Zacks Equity Research
The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.
Express Scripts to Boost Oral Medication With Diabetes Study
by Zacks Equity Research
Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.
Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms
by Zacks Equity Research
The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.
Illumina Teams Up With Telegraph Hill to Form Verogen
by Zacks Equity Research
Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.
Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates
by Zacks Equity Research
Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.
Align Technology-Patterson Dental Deal Expands iTero Reach
by Zacks Equity Research
Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.
LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track
by Zacks Equity Research
LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.
Stryker Recalls Sage Unit Products, Guidance Takes a Hit
by Zacks Equity Research
Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.
Patterson Companies (PDCO) Beats on Q1 Earnings, Keeps View
by Zacks Equity Research
Patterson Companies' (PDCO) Animal Health business continues to contribute to the bottom line. Stable fiscal 2018 guidance instills investor confidence.
Why IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Civitas Solutions (CIVI) to Acquire Habilitative Services
by Zacks Equity Research
Civitas Solutions' (CIVI) proposed acquisition of Habilitative Services will aid the company in capturing the lucrative Minnesota market.
Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm
by Zacks Equity Research
Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.
PerkinElmer Strong on Product Lineup Amid Integration Risks
by Zacks Equity Research
PerkinElmer's (PKI) expanding product portfolio helps it gain global market share. However, the company's regular acquisitions pose integration risks.
Medtronic (MDT) Beats Q1 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) rides high in Q1 on strength in three major business segments.
PAREXEL Ties Up With Osaka International Cancer Institute
by Zacks Equity Research
We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.
Quality Systems Professional Service a Drag, Competition Rife
by Zacks Equity Research
Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.
Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio
by Zacks Equity Research
Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
by Zacks Equity Research
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.